Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiprogestins for contraception?

Helena von Hertzen1, Paul F A Van Look

  • 1UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland. vonhertzenh@who.int

Seminars in Reproductive Medicine
|February 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moving towards the goals of FP2020 - classifying contraceptives.

Contraception·2016
Same author

The World Health Organization's safe abortion guidance document.

American journal of public health·2013
Same author

40 years of innovation in sexual and reproductive health.

Lancet (London, England)·2012
Same author

Complications of first-trimester abortion by vacuum aspiration after cervical preparation with and without misoprostol: a multicentre randomised trial.

Lancet (London, England)·2012
Same author

Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials.

Contraception·2011
Same author

A randomized, double-blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria.

Contraception·2010

Antiprogestins show promise for contraception by blocking progesterone effects. Research is exploring their use in emergency contraception, daily pills, and sequential regimens, seeking more specific compounds for better results.

Area of Science:

  • Reproductive endocrinology
  • Pharmacology

Background:

  • Antiprogestins counteract progesterone, a key reproductive hormone.
  • Mifepristone has been the primary antiprogestin studied for family planning.
  • Previous trials have largely not met expectations for widespread use.

Purpose of the Study:

  • To evaluate the potential of antiprogestins as contraceptive agents.
  • To explore different administration methods for antiprogestin-based contraception.
  • To identify promising antiprogestin compounds beyond mifepristone.

Main Methods:

  • Review of existing studies on antiprogestin efficacy in contraception.
  • Analysis of different dosing strategies and regimens.
  • Consideration of compound-specific properties like target organ affinity.

Related Experiment Videos

Main Results:

  • Antiprogestins show potential in emergency contraception.
  • Daily high-dose antiprogestins may block ovulation.
  • Sequential regimens with a progestin are a promising approach.
  • Mifepristone has limitations; more specific compounds may offer better outcomes.

Conclusions:

  • Antiprogestins are a promising area for contraceptive development.
  • Optimized use may include emergency contraception, daily high-dose regimens, or sequential therapy.
  • Development of more specific antiprogestins is crucial for future success.